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mains limited. A dedicated European research programme 
for ICH is needed to identify ways to reduce the burden of 
ICH-related death and disability. The European Research 
Network on Intracerebral Haemorrhage EURONICH is a mul-
tidisciplinary academic research collaboration that has been 
established to define current research priorities and to con-
duct large clinical studies on all aspects of ICH. 
 Copyright © 2011 S. Karger AG, Basel 
 Epidemiology of Intracerebral Haemorrhage 
 Intracerebral haemorrhage (ICH) encompasses a 
diverse range of conditions, with different underlying 
causes, but similarly poor outcomes  [1] . In brief, causes of 
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 Abstract 
 Over 2 million people are affected by intracerebral haemor-
rhage (ICH) worldwide every year, one third of them dying 
within 1 month, and many survivors being left with perma-
nent disability. Unlike most other stroke types, the incidence, 
morbidity and mortality of ICH have not declined over time. 
No standardised diagnostic workup for the detection of the 
various underlying causes of ICH currently exists, and the ev-
idence for medical or surgical therapeutic interventions re-
 Received: March 31, 2011 
 Accepted: July 1, 2011 
 Published online: October 8, 2011 
 Thorsten Steiner 
 Department of Neurology 
 Heidelberg University Hospital, Im Neuenheimer Feld 400 
 DE–69120 Heidelberg (Germany) 
 Tel. +49 6221 56 38673, E-Mail thorsten-steiner   @   med.uni-heidelberg.de 
 © 2011 S. Karger AG, Basel
1015–9770/11/0325–0409$38.00/0 
 Accessible online at:
www.karger.com/ced 
 Steiner et al. Cerebrovasc Dis 2011;32:409–419410
ICH can be differentiated into arterial small and large 
vessel disease, venous disease, vascular malformation, 
haemostatic disorders, ICH in the context of other dis-
eases and conditions, and spontaneous. ‘Spontaneous’ 
means that no cause has been found with the currently 
available diagnostic tests, though it is assumed that there 
is a cause (cryptogenic). Spontaneous also includes that 
no cause has been found so far, and there is no suspicion 
about a concept for a cause (idiopathic). A proposal for a 
detailed ICH classification by causes is currently pre-
pared in the frame of the new ICH guidelines from the 
European Stroke Organisation. Spontaneous ICH, which 
is apparently unrelated to trauma, has incurred un-
changed global burden over the past decades  [2, 3] . In 
contrast to the declining incidence of ischaemic stroke in 
high-income countries  [4] , the incidence of ICH has been 
constant  [3] . Worldwide, the World Health Organisation 
estimates that 15.3 million strokes occur every year  [5] , of 
which 2–3 million are haemorrhagic. The cost of stroke 
in the European Union has been estimated at 27 billion 
EUR, of which 8.5 billion EUR are indirect costs  [6] . The 
additional cost of ICH is estimated to be 30,000–45,000 
EUR/survivor every year  [7] .
 During the last decade, spontaneous ICH accounted 
for approximately 10% of strokes in high-income coun-
tries and about 20% of strokes in low-/middle-income 
countries, with 1-month case fatalities of 25–35 and 30–
48%, respectively  [4] . Cerebrovascular disease mortality 
also varies widely in Europe  [8] . Unfortunately, the 
1-month case fatality after ICH does not appear to have 
changed over the last few decades  [3] . This is in contrast 
to the recent decline in the case fatality after subarach-
noid haemorrhage  [9, 10] , which may be explained by 
multiple factors  [11] , including advances in endovascular 
treatment of intracranial aneurysms and intensive care 
after intervention  [9, 12] .
 The incidence of spontaneous ICH is higher in Asians 
 [3] , and the major risk factors for ICH include male gen-
der, increasing age, arterial hypertension, excessive alco-
hol consumption, smoking, diabetes mellitus, poor diet 
and obesity (waist-to-hip ratio)  [13, 14] . However, over the 
past decades, the incidence of ICH associated with pre-
stroke hypertension appears to have declined, whereas 
ICH associated with use of antithrombotic drugs and 
presumed cerebral amyloid angiopathy in those aged 
 6 75 years seems to have increased  [2] .
 Impact for Research 
 As life expectancy rises, so will the burden of ICH. We 
need a better understanding of the roles of various risk 
factors for ICH in the elderly, to what extent they are caus-
al and modifiable, and whether demographic transitions 
in low-income countries and low social status result in a 
larger proportion of deaths being due to ICH.
 We need more information on ICH epidemiology in 
low- and middle-income countries to compare racial, 
ethnic and population differences, as well as more esti-
mates of ICH case fatality rates during different epochs 
in order to understand why they appear to have declined 
in some regions but not in others  [3] .
 A joint prospective multinational study on the inci-
dence, prevalence and socio-economic impact of sponta-
neous ICH – ideally – in all European Union countries is 
needed to propose more specific actions to be taken by 
health authorities at European and national levels.
 Pathophysiology of ICH and Impact of Brain Banking 
 Most data on the pathophysiology of human ICH 
come from early macroscopic autopsy studies and de-
scribe neural damage from the hydrostatic pressure of 
ICH. Most instances of ICH occur when small (50- to 
700-  m) penetrating arteries rupture with subsequent 
leaking of arterial blood into the brain parenchyma. The 
mass effect of the haematoma destroys neighbouring 
brain structures and compresses remote brain regions by 
midline shift and herniation. Rebleeding or haematoma 
growth and intraventricular expansion complicate the 
ICH in up to 70% of all patients within 24 h  [15] . The fixed 
shape of the cranium limits its capacity to accommodate 
the volumetric ICH expansion, and haematoma volumes 
over 150 ml almost inevitably lead to death.
 The intact or partially intact brain tissue around the 
haematoma may resemble ischaemic brain, and neurons 
may die by similar mechanisms or may be subject to tox-
ic effects of blood products. However, studies have been 
contradictory about the presence, extent and severity of 
any penumbra around ICH. Blood-brain barrier disrup-
tion and leakage of fluids and proteins contribute to brain 
oedema, which commonly increases over several days 
and may further damage the brain  [16] . At a later stage, 
erythrocyte lysis and release of haemoglobin metabolites, 
iron and thrombin have been shown to trigger neurotox-
ic and apoptotic mechanisms in animals  [17, 18] . Another 
potential pathogenetic mechanism is activation of leuco-
cytes at the injury site within the first few days, attribut-
able to the widespread inflammation seen in animal 
models of ICH. All injuries to brain tissue also change 
genomic expression in the brain  [19] , which is a largely 
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unexplored phenomenon in ICH patients. Experimental 
studies, mostly in rodents, have expanded our knowledge 
of pathophysiology, but are lacking confirmation in hu-
man studies so far. Furthermore, the two most popular 
rodent ICH models are not entirely comparable to human 
ICH, and despite their usefulness in some aspects they 
cannot replace human tissue examinations  [20] .
 Impact for Research 
 Development of novel treatments requires a precise 
understanding of the underlying pathophysiology and 
molecular mechanisms of ICH-related brain injury. 
Therefore, there is an urgent need for establishing large 
multicentre human ICH brain banks based on samples 
from within the haematoma, the vicinity of the haema-
toma, as well as from remote brain regions from patients 
who die at different time points following ICH, in order 
to systematically study macroscopic, microscopic and ul-
trastructural changes.
 Also, it is necessary to examine the roles of candidate 
molecules in causing ICH-related brain damage, to map 
cellular and molecular migration patterns, to study arte-
rial wall microstructure, and to decipher post-ICH brain 
genetics and proteomics in sufficiently large samples.
 Additionally, blood samples should be collected from 
ICH patients at various phases of the disease and stored 
for future research on biomarkers including genome-
wide association studies and candidate gene identifica-
tion with micro-arrays.
 ICH Imaging and Diagnostic Workup 
 Studies on sensitivity and specificity of prehospital 
clinical diagnosis of ICH are contradictory  [21–28] . 
Therefore, brain imaging is the cornerstone for ICH di-
agnosis because haemorrhagic and ischaemic stroke can-
not be differentiated on clinical grounds alone. Brain 
computed tomography (CT) detects symptomatic ICH 
within minutes of symptom onset but may lack sensitiv-
ity if the bleeding is hyperacute (uncoagulated blood) or 
CT brain imaging is delayed for more than 1 week after 
ICH onset (hematoma isodense to brain tissue)  [29] . 
Magnetic resonance imaging (MRI) with T 2 * -weighted 
gradient-recalled echo sequences identifies ICH soon af-
ter onset and reliably detects chronic posthaemorrhagic 
iron deposits  [30] . Initial imaging may also be used as 
part of prognostic scores predicting clinical outcome af-
ter acute ICH  [31] . Hyperacute CT angiography followed 
by a postcontrast scan may in up to 40% identify a ‘spot 
sign’ – 1 or more hyperintense spots in the haematoma – 
representing a contrast leak. Its presence is a recently es-
tablished predictor of haematoma expansion and poor 
outcome  [32–34] . E-learning programmes may permit 
easy implementation in clinical practice  [35] .
 After the ascertainment of the haemorrhagic nature of 
the stroke, a swift diagnosis of the underlying cause can 
expedite management to improve outcome or prevent re-
current ICH. For both MRI and CT, baseline and serial 
studies can be used to identify patients who may benefit 
from acute interventions (e.g. anticoagulation for intra-
cranial venous thrombosis or placement of an external 
ventricular drain for hydrocephalus). The reliable detec-
tion of an underlying arterial aneurysm, arteriovenous 
malformation or dural arteriovenous fistula may require 
additional intra-arterial digital subtraction angiography 
because timely treatment can prevent recurrent ICH  [1] .
 In line with the low level of evidence of the existing in-
ternational recommendations  [36–38] , clinical practice 
varies widely across Europe: In a survey of current prac-
tice, the types and timing of investigations varied con-
siderably between specialties and countries. Generally, 
younger age, a lobar bleeding location and the absence of 
pre-existing arterial hypertension prompt further diag-
nostic studies beyond the initial CT imaging  [39] . None of 
these factors, however, reliably predicts any underlying 
vascular pathology. MRI and angiographic imaging seem 
worthwhile depending on the patient’s clinical condition 
 [40] , but the availability and choice of these modalities will 
depend on local resources, regional standards and nation-
al healthcare systems. Until further studies of the diagnos-
tic accuracy of non-invasive investigations such as CT or 
magnetic resonance angiography have been performed, 
these techniques cannot replace intra-arterial digital sub-
traction angiography for the investigation of ICH  [39] .
 Impact for Research 
 Given the large variety of underlying vascular pathol-
ogies, the concept of ‘primary’ ICH should be replaced by 
a more systematic stratification into specific diagnostic 
subtypes. Testable ICH standard diagnostic criteria need 
to be defined by underlying aetiology, including working 
criteria for diagnostic certainty according to imaging and 
other diagnostic tools.
 The increasing sensitivity of diagnostic tests, changes 
in the epidemiology of ICH and discovery of newly iden-
tified risk factors ask for a new classification of ICH ac-
cording to aetiological subgroups. Planned as part of the 
updated European Stroke Organisation guidelines on 
ICH diagnosis and management, a new ICH classifica-
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tion will help to standardise inclusion criteria for future 
observational research and controlled clinical trials.
 Future research should also focus on the appropriate 
type and timing of diagnostic investigations after sponta-
neous ICH onset. This includes development of a decision 
tree defining standard diagnostic and management algo-
rithms, and the most cost-effective strategies for investi-
gating patients at older ages and in resource-poor settings.
 More refined imaging tools and diagnostic signs (e.g. 
the spot sign on postcontrast multidetector row CT) may 
help to better define subgroups at risk for haematoma ex-
pansion or rebleeding  [32, 41] . Only few reports exist on 
the spot sign on contrast-enhanced MRI  [42, 43] and 
warrant further study. This may improve patient selec-
tion for future clinical trials in acute ICH as patients with 
a high risk of haematoma expansion may also show the 
highest treatment effect  [44, 45] .
 Alternative imaging tools, such as transcranial ultra-
sound, should be explored for early ICH diagnosis and 
non-invasive follow-up imaging  [46] . Clinical grading 
scales predicting outcome after ICH could be improved 
by identifying the underlying cause and incorporating 
more specific imaging data  [47] .
 Prevention 
 Currently established predictors of ICH include mod-
ifiable risk factors (arterial hypertension, diabetes melli-
tus, excessive alcohol consumption, smoking, poor diet, 
overweight, quality of anticoagulant therapy) and non-
modifiable risk factors such as male gender, increasing 
age, ethnic origin and certain genetic predispositions  [13, 
48] . Presence of 1 or more of these factors may lead to 
subsequent structural changes of the small brain vessels, 
including arteriolosclerosis, lipohyalinosis and eventual 
formation of micro-aneurysms. The various effects of 
many risk factors may result in so-called cerebral small 
vessel disease, which underlies many ICH cases. The pop-
ulation prevalence of cerebral small vessel disease – even 
without ICH – increases with age and may lead to pro-
gressive cognitive decline and mainly determines the 
burden of vascular dementia in the general population.
 Medical Prevention of ICH 
 As for ischaemic stroke prevention, guidelines recom-
mend that survivors of ICH should stop smoking, limit 
their alcohol consumption and actively treat any con-
comitant risk factors mentioned above, in particular el-
evated blood pressure  [36–38] . After the acute phase of 
ICH, the large randomised PROGRESS trial found that 
blood pressure reduction (using the angiotensin-convert-
ing enzyme inhibitor perindopril and the diuretic indap-
amide) was beneficial in the prevention of future vascular 
events  [49] . The effect was particularly strong for second-
ary prevention of ICH: an average systolic blood pressure 
reduction of 12 mm Hg decreased the risk of recurrent 
ICH by up to 76%  [50] .
 ICH prevention (primary and secondary) becomes 
particularly important in patients with a need for oral 
anticoagulation  [51] . The introduction of new oral anti-
coagulants may decrease the risk of (re)bleeding com-
pared to warfarin by as much as 1/3 to 2/3  [52–54] . How-
ever, the problem of oral anticoagulant therapy-related 
ICH will remain and possibly even increase in absolute 
numbers. There are two reasons for this: (1) the new drugs 
may be prescribed more liberally because of a better safe-
ty profile, and (2) the number of patients with atrial fibril-
lation is expected to increase substantially over the next 
decade  [55] . Just as for warfarin-related ICH, questions 
like best acute treatment and restart of secondary preven-
tion will need to be answered.
 Surgical Prevention of ICH 
 The quality of non-invasive brain imaging tools, such 
as CT, MRI, as well as vascular imaging by means of CT 
angiography and magnetic resonance angiography, has 
improved constantly over the past. The increased acces-
sibility leads to a growing number of incidentally diag-
nosed haemorrhage-prone vascular malformations at a 
stage before actual ICH or even clinical symptoms have 
occurred. Unruptured aneurysms, unruptured brain 
arteriovenous malformations and incidental cavernous 
malformations often represent a management dilemma 
because treatment decisions have to consider the risk of 
invasive versus non-invasive strategies. Depending on le-
sion type, size and location, possible interventional tech-
niques include neurosurgery, endovascular embolisation 
or stereotactic radiosurgery. So far, however, no con-
trolled clinical study has proven the clinical benefit of any 
of such interventions for primary haemorrhage preven-
tion in affected patients  [56] .
 Impact for Research 
 Longitudinal population-based cohort studies will 
have to test the preventive effect of active risk factor mod-
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ification on the incidence and recurrence rate of ICH. 
The impact may be different according to subtypes of un-
derlying small vessel disease (e.g. amyloid angiopathy, 
hypertension-induced arteriolosclerosis or genetic small 
vessel disease). Improved risk factor management may 
also have a favourable effect on the burden of vascular 
dementia in the general population. Also, there is a need 
for studying the double risk of stroke with small vessel 
disease (ischaemic and haemorrhagic stroke) in future 
ICH research, including adequate outcome measures in 
future ICH research.
 For an increasing number of patients diagnosed with 
haemorrhage-prone but as yet unruptured vascular le-
sions (such as aneurysms, arteriovenous or cavernous 
malformations), controlled clinical ICH prevention trials 
are needed to compare the risk/benefit ratio of preventive 
lesion eradication versus non-interventional manage-
ment. One international randomised clinical trial evalu-
ating the management of unruptured brain arteriove-
nous malformations is currently ongoing (www.aru-
bastudy.org) including many study sites across Europe.
 Acute Medical ICH Treatment 
 Stroke Unit and Neurocritical Care Unit Management 
 The latest Cochrane Review update by the Stroke Unit 
Trialist’s Collaboration confirmed the benefit of stroke 
unit care for unselected stroke patients  [57] . Admission 
to a neurological/neurosurgical intensive care unit has 
been shown to be associated with a reduced mortality rate 
after ICH in an observational study design  [58] . While 
there are no indications that patients with ICH have less 
benefit than patients with ischaemic stroke, studies were 
not powered to detect such differences. The European 
Stroke Organisation guidelines recommend standard 
stroke care defined as dedicated care with trained per-
sonnel, monitoring of physiological parameters and early 
mobilisation. There is largely only class IV evidence for 
any single general care item such as antibiotic treatment 
of respiratory infections, early mobilisation or use of a 
nasogastric tube. Whether patients with ICH respond 
differently to any of these measures is unclear, and early 
decision-making regarding ‘do not resuscitate’ orders 
may systematically bias available data sets  [59] .
 Volume of ICH and presence of intraventricular haem-
orrhage were repeatedly found to be the two major pre-
dictors of death or severe disability in the acute phase 
after spontaneous ICH  [60–62] . Volumes of ICH or intra-
ventricular haemorrhage or both increase within 24 h in 
at least 70% of patients  [15] . Therefore, treatments aimed 
at reduction of volume, restriction of growth and remov-
al of ventricular haemorrhage may improve outcome. 
Furthermore, increasing perihaematoma oedema may 
add to the mass effect. However, the association between 
perihaematoma oedema and acute/subacute morbidity 
and mortality appears contradictory  [63, 64] .
 Methods to predict the likelihood of ICH growth have 
been proposed and need verification (e.g. density and 
shape of the ICH on CT  [65] , or spot sign on CT angiog-
raphy  [32, 34, 45] ). Haematoma expansion may also lead 
to increased intracranial pressure. Patients with a Glas-
gow Coma Scale score  ^  8 requiring intubation and ar-
tificial ventilation may benefit from an intraventricular 
or parenchymal intracranial pressure monitoring. In-
creased intracranial pressure is treated according to ac-
cepted general guidelines, including osmotherapy (man-
nitol or hypertonic saline as boluses), and intermittent 
cautious short-term hyperventilation (aiming at p CO 2 
32–35 mm Hg), whereas decompressive craniectomy and 
moderate hypothermia might be efficacious  [36, 37] . 
However, none of these procedures has been subject to 
controlled clinical trials.
 Haemostatic Therapy 
 Non-surgical concepts to restrict growth include the 
use of haemostatic agents and blood pressure lowering. 
  -Amino caproic acid (EACA), tranexamic acid (TXA) 
and activated recombinant factor VII (rFVIIa) were used 
in trials for spontaneous ICH  [61, 66–68] .
 The 4 randomized controlled trials of haemostatic 
drugs for acute ICH included 423 placebo and 975 pa-
tients who received haemostatic drug, 973 on rFVIIa and 
2 EACA, and thus this comparison was mainly a com-
parison between placebo and rFVIIa  [69] . Haemostatic 
drug therapy did not reduce the case fatality and risk of 
death and dependency on modified Rankin Scale within 
90 days, despite a significant reduction in haematoma 
growth. There was a trend towards more participants on 
rFVIIa experiencing thrombo-embolic serious adverse 
events. A post hoc analysis suggested several reasons why 
the largest haemostatic drug trial (FAST  [61] ) showed a 
neutral result, including a treatment time window be-
yond 2.5 h, median patient age  1 70 years, average intra-
ventricular haemorrhage volume  1 5 ml, and ICH vol-
ume of more than 60 ml  [44] . This implies that a shorter 
time to detection (e.g. by CT) may improve the power of 
subsequent trials.
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 EACA was evaluated in a small retrospective study, 
which included 5 patients within 12 h after an acute ICH. 
These patients were treated with EACA intravenously 5 g 
during the 1st hour and with 1 g/h during the following 
23 h  [66] . Haematoma enlargement occurred in 3 of 5 pa-
tients, while it occurred in 2 of 9 patients who were not 
treated with EACA.
 TXA works when the coagulation mechanism has 
been set off and exhibits its haemostatic effect by inhibit-
ing plasminogen  [70] , thereby inhibiting the cascade of 
enzymes which dissolve a thrombus. Its use for a variety 
of other indications suggests that it may be effective in 
reducing ICH growth. A protocol of rapid infusion of 
TXA (2 g over 10 min) and blood pressure restriction 
(systolic blood pressure below 150 mm Hg) was used in 
223 consecutive and retrospectively analysed patients 
within 24 h after spontaneous ICH  [67] . Haematoma en-
largement (defined as  6 20% volume increase) was ob-
served in 8 (4.3%) of 188 patients. The CRASH-2 trial 
included trauma patients and compared the risk of death 
due to bleeding in 10,096 patients who were treated with 
TXA and 10,115 who received placebo. Death due to 
bleeding was significantly reduced from 574 (5.7%) in the 
placebo group to 489 (4.9%) in the TXA group for all 
causes of trauma  [71] . No significant difference was found 
in the subgroup of patients with traumatic brain injury, 
though the trial was not powered for this analysis. A Co-
chrane review of the randomised trials with TXA in pa-
tients undergoing elective surgery identified 53 studies 
including 3,836 participants  [72] , and TXA reduced the 
need for blood transfusion by one third. TXA has been 
shown to decrease early rebleeding after aneurysmal sub-
arachnoid haemorrhage from 10.8% among controls to 
2.4%, while reducing mortality from 16.3 to 12.9%; how-
ever, the doses and treatment durations differ from those 
used for ICH so far  [73] . Whether the occurrence of 
thrombo-embolic complications is different, e.g. com-
pared with rFVIIa treatment, is not known.
 Blood Pressure Control 
 Mechanistically it seems plausible that elevated blood 
pressure is a driving force for haematoma enlargement. 
On the other hand, lowering blood pressure too much 
may lead to ischaemia. However, several recent publica-
tions suggest the latter being less important  [74, 75] . After 
positron emission tomography studies had found no evi-
dence of hypoperfusion or increased oxygen extraction in 
the brain tissue surrounding the ICH, it was assumed that 
antihypertensive treatment would not harm the perihae-
matomal tissue  [76] . Intensive lowering of blood pressure 
was applied in the ‘intensive blood pressure reduction in 
acute cerebral haemorrhage trial’ (INTERACT)  [77] . 
Overall, 400 patients were randomised to either intensive 
(systolic blood pressure  ^  140 mm Hg within 1 h) or 
guideline-based blood pressure treatment (systolic blood 
pressure  ^  180 mm Hg). Intensive blood pressure restric-
tion for 7 days turned out to be feasible, safe and to reduce 
haematoma growth on 24-hour follow-up imaging. The 
Antihypertensive Treatment of Acute Cerebral Haemor-
rhage (ATACH) trial looked at three different blood pres-
sure target groups in an escalating design – blood pressure 
was kept within 3 different ranges for 18–24 h: group 1 
(n = 18) 170–200 mm Hg, group 2 (n = 20) 140–170 mm 
Hg and group 3 (n = 22) 110–140 mm Hg  [78] . The ob-
served proportions of neurological deterioration and seri-
ous adverse events were below the prespecified safety 
thresholds, and the 3-month mortality rate was lower 
than expected in all systolic blood pressure tiers.
 Impact for Research 
 The application of haemostatic drugs in spontaneous 
ICH seems to reduce haematoma growth, despite the fact 
that different definitions of growth or haematoma en-
largement were used  [79] . Still there is no study that has 
shown that reduction of haematoma enlargement has a 
beneficial clinical effect. By far, most information has 
come from trials on rFVIIa, but other drugs, e.g. TXA, 
might turn out to be effective. The INTERACT 2 phase 
III trial is ongoing to establish the efficacy and safety of 
aggressive blood pressure lowering compared to guide-
line-based blood pressure targets on death and depen-
dency at 3 months; the trial includes many sites in Europe 
 [80] . The interaction between haemostatic and antihy-
pertensive approaches to treatment will need to be estab-
lished as part of subsequent haemostatic drug trials.
 ICH and ischemic stroke trials have some aspects in 
common, for example outcome predictors such as time 
window, lesion volume and clinical status on admission, 
or outcome measures like modified Rankin Score, Na-
tional Institutes of Health Stroke Scale, Glasgow Outcome 
Score or Barthel index. Yet, important differences should 
be considered in ICH research, particularly outcome pre-
dictors like intraventricular volume, haematoma expan-
sion predictors like spot sign and outcome measures like 
socio-economic impact and the association between risk 
factors and pathology (e.g. hypertension and location). 
Another factor that needs to be studied further is the im-
pact of do-not-resuscitate orders on outcome in ICH.
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 Acute Surgical ICH treatment 
 About 10% of spontaneous ICH are located in the 
brainstem or cerebellum  [81] . Current guidelines recom-
mend evacuation of cerebellar ICH when its diameter ex-
ceeds 2–3 cm, if symptomatic hydrocephalus is present or 
if brainstem compression arises  [37, 38] . The application 
of an external ventricular drain is recommended in case 
of hydrocephalus and signs of clinical deterioration. 
None of these recommendations are based on prospective 
clinical trials with clearly defined selection criteria. The 
same holds true for the management of external ventric-
ular drains during the course of the disease  [82, 83] .
 While there is little doubt that the removal of an ex-
panding posterior fossa haematoma improves acute ICH 
outcome, controversy exists about surgical interventions 
for spontaneous supratentorial ICH. Data collected from 
non-randomised studies have usually shown that the out-
come has been worse in the surgically treated group. This 
is because the most severely affected patients have been 
subjected to surgery while the less severe cases have been 
treated conservatively  [84] .
 The STICH trial was the largest prospective ran-
domised controlled trial of early surgery compared with 
initial conservative treatment  [85] . In this study, 1,033 pa-
tients were randomised within 72 h to initial conservative 
treatment or early surgery. The result was neutral for 
death and disability at 3 months, but a subgroup analysis 
suggested that superficial lobar haematomas treated with 
craniotomy were more likely to benefit from early surgi-
cal intervention.
 A meta-analysis of the 13 prospective randomised con-
trolled trials of surgery versus conservative treatment has 
demonstrated a significant reduction in mortality and a 
strong indication of reduced morbidity as well  [86, 87] . A 
14th trial has recently been published also suggesting that 
(minimally invasive) surgical intervention is of value  [88] . 
One problem of small trials that looked at surgery within 
4 h though was an increased rate of rebleeding  [89] .
 Impact for Research 
 Both ICH and intraventricular haematoma volumes 
play a key role in the management of ICH. As in other 
stroke types, the timing between ICH onset and treat-
ment initiation in any surgical ICH trial may be crucial, 
since most of the volume expansion occurs within the 
first 24 h.
 The role of surgery within this time frame is as yet un-
clear, but the issue is subject to several currently ongoing 
clinical trials: one prospective randomised controlled tri-
al has been initiated (STICH II) to test the effect of sur-
gery in patients with superficial lobar haematomas with-
out ventricular haemorrhage or hydrocephalus. A target 
of 600 patients should be achieved by the autumn of 2011; 
many European sites are currently involved.
 Another trial of minimal intervention surgery 
(MISTIE) is evaluating the role of intracavity tissue plas-
minogen activator with catheter drainage also for supra-
tentorial spontaneous haematomas. A third ongoing 
prospective randomised controlled trial (CLEAR III) is 
randomising patients with ventricular haemorrhage to 
intraventricular recombinant tissue plasminogen activa-
tor administration compared to placebo and catheter 
drainage. Efficacy of this approach has been shown so far 
only in small prospective trials  [90, 91] .
 Clinical trials with clearly defined selection criteria on 
surgical management of cerebellar ICH and hydrocepha-
lus are needed. Also, the question when to place, change 
or replace an external ventricular drain in patients with 
ICH-related hyrocephalus needs to be answered in con-
trolled clinical trials.
 Conclusion and Perspectives 
 Spontaneous ICH does affect a significant proportion 
of the European and worldwide population. The mortal-
ity is significantly higher than in ischaemic stroke, and 
the prognosis is still poor, creating a large socio-econom-
ic burden. However, very few management strategies are 
supported by good evidence, and specific research pri-
orities for ICH have been lacking so far in Europe  [92] . 
On the other hand, promising results from studies on 
pathophysiological mechanisms and from clinical trials, 
as well as combined efforts from different research fo-
cuses in the area, provide optimism for the future.
 As response to a lacking European research agenda for 
ICH, a dedicated academic initiative has now been estab-
lished to constitute a multicentre European Network for 
ICH research (called EURONICH, see the appendix). The 
network focuses on setting research priorities, planning 
and executing high-impact large clinical studies, includ-
ing controlled clinical trials, the collection of blood sam-
ples for DNA and biomarker studies, a brain imaging ar-
chive, and a brain tissue bank for deciphering molecular 
and cellular mechanisms of ICH and its underlying dis-
ease entities. Multidisciplinary diagnostic and therapeu-
tic strategies should be optimised sharing the expertise of 
vascular neurology, diagnostic and interventional neuro-
radiology, neurosurgery, anaesthesiology, neuropsychol-
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ogy and rehabilitation, to name but a few. The ultimate 
aim is to improve patient care across all member states of 
the European Union, and beyond. Interested colleagues 
and neurovascular teams in Europe are welcome to join 
the effort (http://www.euronich.de).
 Appendix 
 EURONICH is an initiative of researchers and their coworkers 
in the field of ICH from 14 European countries (http://www.
euronich.de). It is an open network that welcomes other clinical 
and basic science researchers to participate in this multidisci-
plinary collaboration. Finances used to make the EURONICH 
initiative come to life come from money that is supplied by insti-
tutional research support, as well as from research grants and on-
going clinical studies in the area of ICH.
 Members of EURONICH have performed several planning 
meetings on research projects and scientific sessions during the 
European Stroke Conferences in 2009 (Stockholm, Sweden), 2010 
(Barcelona, Spain) and 2011 (Hamburg, Germany).
 Currently funded ICH-related studies within the EURONICH 
network include: (1) ARUBA – A randomised trial of unruptured 
brain arteriovenous malformations; sponsor: NIH/NINDS (USA); 
(2) INCH – international normalised ratio normalisation in pa-
tients with coumadin-related ICH; sponsor: Heidelberg University 
Hospital (Germany); (3) INTERACT2 – Second Intensive Blood 
Pressure Reduction in Acute Cerebral Haemorrhage Trial; spon-
sor: National Health and Medical Research Council (Australia).
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